التداخل بين كلوبيدوغريل ودولوكسيتين

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding.

SSRIs and SNRIs Since selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) affect platelet activation, the concomitant administration of SSRIs and SNRIs with clopidogrel may increase the risk of bleeding.

Concomitant use of antiplatelet drugs and anticoagulants may increase this risk.

Drugs that Interfere with Hemostasis Prevention or Management Closely monitor for bleeding for patients receiving an antiplatelet or anticoagulant drug when Duloxetine Delayed-Release Capsules are initiated or discontinued [Warnings and Precaution ( 5.5 )] .

Mechanism and Clinical Effect(s) Concomitant use of Duloxetine Delayed-Release Capsules with an antiplatelet or anticoagulant drug may potentiate the risk of bleeding.